Expanded Access Treatment Protocol With DCA for Patients With PDCD

Summary

Expanded Access (EA) will provide a transition to continue therapy for those patients who are currently in the open label extension of the Phase III study, SL 1009-01, while also allowing new patients diagnosed with PDCD who meet the eligibility criteria to also have access to therapy that would be otherwise unavailable.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications